Lupin. has filed a patent for a drug delivery system for contraception, involving ultra-low doses of steroidal compounds to minimize burst release. The system, administered vaginally, delivers ethinyl estradiol and etonogestrel for a contraceptive effect over a specified period. GlobalData’s report on Lupin gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Lupin Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Lupin, Cancer treatment biomarkers was a key innovation area identified from patents. Lupin's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

Ultra-low dose drug delivery system for contraception

Source: United States Patent and Trademark Office (USPTO). Credit: Lupin Ltd

The patent application (Publication Number: US20230404911A1) describes a drug delivery system designed for contraception by administering it to a subject's vaginal tract. The system consists of a core containing ethinyl estradiol and etonogestrel, covered by a membrane. When in the vaginal tract, the system delivers effective doses of both compounds over a specified period, producing a contraceptive effect. Importantly, the system releases less than 0.013 mg per day of ethinyl estradiol, with the period of effectiveness ranging from 21 days to 3 months post-administration.

Furthermore, the patent details the method of contraception using this system, involving positioning it in the vaginal tract for a specific period before removal. The system releases controlled amounts of ethinyl estradiol and etonogestrel daily, ensuring contraceptive efficacy. The patent also specifies the composition of the core and membrane, highlighting the use of specific thermoplastic polymers or elastomers. Overall, the patent outlines a novel drug delivery system for contraception that offers precise dosing and extended effectiveness, potentially improving user compliance and convenience.

To know more about GlobalData’s detailed insights on Lupin, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies